- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01216657
Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma
연구 개요
상세 설명
This is a single agent 2-step phase 2 study with a one-year follow-up to evaluate the antitumor activity of Sunitinib administered in treatment cycles of 6 weeks duration (4 weeks treatment and 2 weeks rest) in patients with chemo-refractory melanoma. If the first step shows sufficient efficacy and tolerability the study will continue to step 2. Treatment will continue for 9 months or until disease progression or until intolerable adverse events occur. Subsequently the patients will be followed up for 1 year. Tumor assessment will be performed at baseline, at the end of cycle 1,2,3 and subsequently at the end of every uneven cycle (5,7,9,…).
A total of 40 patients will be enrolled in this trial.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Frankfurt/Main, 독일, 60488
- Krankenhaus Nordwest
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male and female patients aged 18 years and older.
- Diagnosis of unresectable (Stage III) or metastatic (Stage IV), histologically or cytologically proven, melanoma without clinically meaningful surgical or radiotherapeutical options except for mucosal or ocular origin of the primary tumor.
- Subjects must have completed a first or second line chemotherapy or be progressed under chemotherapeutic treatment. The previous treatment must have included DTIC alone or in combination
- Performance status of 0 to 2 on the ECOG scale
- Life expectancy > 12 weeks.
- Patients must be able to swallow Sunitinib capsules.
- Evidence of measurable disease according to the RECIST criteria
- Prior radiation therapy allowed if completed at least 2 weeks and any major surgery allowed if completed at least 4 weeks prior to first dose of Sunitinib.
- Resolution of all acute toxic side effects of prior therapy or surgical procedures to grade < 1 NCI-CTC (except for laboratory values).
Adequate organ function including the following:
- platelets > 100 x 109/L
- hemoglobin > 8 g/dl
- absolute neutrophils count (AGC) > 1.5 x 109/L.
Hepatic:
- bilirubin <=1.5 times upper limit of normal (ULN)
- aspartate transaminase (AST) and alanine transaminase (ALT) <=2.5 times normal (AST and ALT <=5.0 times normal is acceptable if liver function abnormalities are due to underlying malignancy).
- INR < 1.5 or a PTT within normal limits.
- Subjects must not have any evidence of a bleeding diathesis.
Renal:
- Serum creatinine < 1.5 x ULN
- serum calcium < 1.2 mg/dl.
- Pancreatic:
- Serum lipase and amylase within normal range.
- Signed and dated informed consent
Exclusion Criteria:
- Prior treatment with ras-raf-MEK-ERK signaling pathway inhibitors (including trastuzumab, sorafenib, farnesyl transferase inhibitors or MEK inhibitors), or treatment with drugs which target VEGF (such as bevacizumab).
- Radiotherapy, except palliative radiotherapy during study participation as described.
- Known active infection (i.e. HIV, chronic hepatitis B or C, at the discretion of the investigator)
- History of organ allograft or stem cell transplantation.
- Coexisting second malignancy (excluding basal or squamous cell carcinoma of the skin, superficial bladder cancer and in situ carcinoma of the cervix with no evidence of recurrence) or history of prior malignancy
- Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (> hemicolectomie or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis.
- Current history of chronic diarrhea defined as persisting diarrhea for more than 3 weeks at study entry due to any reason.
Any of the following events prior to starting the trial treatment: *clinically evident congestive heart failure, as defined by New York Health Association (NYHA) > class II
- Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2
- Atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- Subjects on beta-blockers and digoxin must be monitored closely
- QT-interval > 450 msec
- Risk factors for torsade-de-pointes-tachycardia (i.e.. Hypokalaemia, congenital Long-QT-syndrome)
- Active coronary artery disease or ischemia (myocardial infarction within the last 6 months prior to study entry)
- Coronary/peripheral artery bypass graft
- Cerebrovascular accident or transient ischemic attack
- Active disseminated intravascular coagulation, or history of clinically significant bleeding within the past 6 months, including gross hemoptysis or haematuria, or underlying coagulopathy
- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with trial participation or trial drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into the trial.
- Participation in any other clinical trial within the last 3 weeks.
- Pregnant or lactating women.
- Known allergic/hypersensitivity reaction to any of the components of the treatment, or known drug abuse/alcohol abuse.
- Active CNS metastatic or meningeal tumors.
- Patients with seizure disorders requiring medication (such as antiepileptics, the use of carbamazepine, phenytion an phenobarbital is prohibited).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: sunitinib
50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
|
50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
clinical benefit rate cycle 1-3
기간: tumor assessment every 6 weeks
|
clinical benefit rate defined as a CR + PR + SD > 4 months duration
|
tumor assessment every 6 weeks
|
clinical benefit rate cycle 4 and more
기간: tumor assessment every 12 weeks
|
clinical benefit rate defined as a CR + PR + SD > 4 months duration
|
tumor assessment every 12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
response rate cycle 1-3
기간: tumor assessment every 6 weeks
|
response rate defined as CR+PR
|
tumor assessment every 6 weeks
|
progression free survival
기간: follow-up one year
|
follow-up one year
|
|
overall survival
기간: follow-up for one year
|
follow-up for one year
|
|
response rate cycle 4 and more
기간: every 12 weeks
|
response rate defined as CR+PR
|
every 12 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Elke Jäger, Prof. Dr., Krankenhaus Nordwest
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- S379 SUMA
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Sunitinib에 대한 임상 시험
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.완전한
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)종료됨상세불명의 성인 고형 종양, 프로토콜 특정 | 전이성 암 | 인지/기능적 효과미국
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)완전한
-
Washington University School of MedicinePfizer완전한